HER3-DXd

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

Conditions

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

Trial Timeline

— → —

NCT ID

NCT06099639

About HER3-DXd

HER3-DXd is a pre-clinical stage product being developed by Daiichi Sankyo for Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT06099639. Target conditions include Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer.

What happened to similar drugs?

1 of 4 similar drugs in Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer were approved

Approved (1) Terminated (0) Active (3)

✅Crysvita (burosumab-twza) TreatmentUltragenyx PharmaceuticalApproved

🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3

🔄Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3

🔄Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, CapecitabineRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06099639	Pre-clinical	Completed	—	—	Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
NCT06172478	Phase 2	Recruiting	Feb 26, 2024	Oct 10, 2028	Advanced Solid Tumor

Competing Products

13 competing products in Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
Erlotinib	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
KRN23	Kyowa Kirin	Phase 2	35
SHR6390 + placebo	Jiangsu Hengrui Medicine	Phase 3	44
ABT-414	AbbVie	Pre-clinical	26
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)	Merck	Phase 3	40
Venetoclax + Fulvestrant	Roche	Phase 2	27
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine	Roche	Phase 3	40
Palbociclib + Everolimus + Exemestane	Pfizer	Phase 1/2	32
Palifermin	Swedish Orphan Biovitrum	Phase 1/2	24
Crysvita (burosumab-twza) Treatment	Ultragenyx Pharmaceutical	Approved	37
FDX104 (4% Doxycycline)	Vyne Therapeutics	Phase 2	25
ATR-04	Azitra	Phase 1/2	14